Skip to main content
Erschienen in: Irish Journal of Medical Science (1971 -) 1/2014

01.03.2014 | Original Article

Fertility preservation in young females with non-gynaecologic malignancy: an emerging speciality

verfasst von: C. Smyth, I. Robertson, L. Higgins, K. Memeh, M. O’Leary, M. Keane, W. Khan, K. Barry

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

As new treatment and research advances continue to improve the prognosis of cancer patients, oncologists and surgeons are increasingly faced with the issue of fertility protection and preservation. Cancer patients are frequently exposed to gonadotoxic chemotherapy and radiation therapy as a component of their treatment regimens. There are currently various anticipatory techniques available to women who wish to retain future reproductive ability, the most successful of which involves oocyte retrieval followed by in vitro fertilisation and embryo cryopreservation. Innovative methods include oocyte cryopreservation, ovarian follicle cryopreservation and oophoropexy.

Aim

The aim of this study was to examine our combined experiences at Mayo General Hospital of treating female patients (<30 years) with non-gynaecologic malignancy and requiring referral to the HARI Unit during a 6-year period (2007–2012). Emphasis was placed on reviewing the fertility-preservation options available.

Methods

The hospital inpatient enquiry system was inspected for all cases of non-gynaecologic malignancy referred for fertility preservation from 2007 to 2012.

Results

Three cases of non-gynaecologic malignancy in young females, with an intention to protect and preserve future fertility were identified. The primary treatment plan did not initially incorporate input from a gynaecology or fertility specialist. It was after concerted inquiry and reflection by both physician and patient that oncofertility consultation was sought.

Conclusion

The responsibility is on both physicians and surgeons to consider a more holistic approach to cancer care in young female patients, which focuses not only on the elimination of malignancy but also on preservation of fertility and quality of life.
Literatur
1.
Zurück zum Zitat Armuand GM, Rodriguez-Wallberg KA, Wettergren L et al (2012) Sex differences in fertility-related information received by young adult cancer survivors. J Clin Oncol 30:2147PubMedCrossRef Armuand GM, Rodriguez-Wallberg KA, Wettergren L et al (2012) Sex differences in fertility-related information received by young adult cancer survivors. J Clin Oncol 30:2147PubMedCrossRef
2.
Zurück zum Zitat Bines J, Oleske DM, Cobleigh MA (1996) Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14:1718–1729PubMed Bines J, Oleske DM, Cobleigh MA (1996) Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14:1718–1729PubMed
3.
Zurück zum Zitat Blumenfeld Z (2007) How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist co-treatment in addition to cryopreservation of embryo, oocytes, or ovaries. Oncologist 12:1044–1054PubMedCrossRef Blumenfeld Z (2007) How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist co-treatment in addition to cryopreservation of embryo, oocytes, or ovaries. Oncologist 12:1044–1054PubMedCrossRef
4.
Zurück zum Zitat Casper RF, Mitwally MF (2006) Aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab 91:760–771PubMedCrossRef Casper RF, Mitwally MF (2006) Aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab 91:760–771PubMedCrossRef
6.
Zurück zum Zitat Clough KB, Goffinet F, Labib A et al (1996) Laparoscopic unilateral ovarian transposition prior to irradiation: prospective study of 20 cases. Cancer 77:2638–2645PubMedCrossRef Clough KB, Goffinet F, Labib A et al (1996) Laparoscopic unilateral ovarian transposition prior to irradiation: prospective study of 20 cases. Cancer 77:2638–2645PubMedCrossRef
8.
Zurück zum Zitat Irsan I, Akisue T, Hara H et al (2007) Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo. Anticancer Res 27:423–429PubMed Irsan I, Akisue T, Hara H et al (2007) Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo. Anticancer Res 27:423–429PubMed
10.
Zurück zum Zitat Matsuo G, Ushijima K, Shinagawa A et al (2007) GnRH agonist acts as ovarian protection in chemotherapy induced gonadotoxicity: an experiment using a rat model. Kurume Med J 54:25–29PubMedCrossRef Matsuo G, Ushijima K, Shinagawa A et al (2007) GnRH agonist acts as ovarian protection in chemotherapy induced gonadotoxicity: an experiment using a rat model. Kurume Med J 54:25–29PubMedCrossRef
11.
Zurück zum Zitat Meirow D, Nugent D (2001) The effects of radiotherapy and chemotherapy on female reproduction. Human Reprod Updat 7:535–543CrossRef Meirow D, Nugent D (2001) The effects of radiotherapy and chemotherapy on female reproduction. Human Reprod Updat 7:535–543CrossRef
14.
Zurück zum Zitat Noyes N, Porcu E, Borini A (2009) Over 900 oocyte cryopreservation babies born with no apparent increase in congenital anomalies. Reprod Biomed Online 18:769–776PubMedCrossRef Noyes N, Porcu E, Borini A (2009) Over 900 oocyte cryopreservation babies born with no apparent increase in congenital anomalies. Reprod Biomed Online 18:769–776PubMedCrossRef
15.
Zurück zum Zitat Oktay K, Sonmezer M (2004) Ovarian tissue banking for cancer patients: fertility preservation, not just ovarian cryopreservation. Hum Reprod 19:477–480PubMedCrossRef Oktay K, Sonmezer M (2004) Ovarian tissue banking for cancer patients: fertility preservation, not just ovarian cryopreservation. Hum Reprod 19:477–480PubMedCrossRef
16.
Zurück zum Zitat Oktay K, Buyuk E, Veeck L et al (2004) Embryo development after heterotopic transplantation of cryopreserved ovarian tissue. Lancet 363:837–840PubMedCrossRef Oktay K, Buyuk E, Veeck L et al (2004) Embryo development after heterotopic transplantation of cryopreserved ovarian tissue. Lancet 363:837–840PubMedCrossRef
17.
Zurück zum Zitat Paik S, Shak S, Tang G et al (2004) Multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826PubMedCrossRef Paik S, Shak S, Tang G et al (2004) Multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826PubMedCrossRef
18.
Zurück zum Zitat Parra SA (2000) Cytotoxic chemotherapy in the treatment of nonmalignant disease. J Intraven Nurs 23:359–365PubMed Parra SA (2000) Cytotoxic chemotherapy in the treatment of nonmalignant disease. J Intraven Nurs 23:359–365PubMed
19.
Zurück zum Zitat Rastogi P, Anderson SJ, Bear HD et al (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26:778–785PubMedCrossRef Rastogi P, Anderson SJ, Bear HD et al (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26:778–785PubMedCrossRef
20.
Zurück zum Zitat Schmidt KL, Andersen CY, Loft A et al (2005) Follow-up of ovarian function post-chemotherapy following ovarian cryopreservation and transplantation. Hum Reprod 20:3539–3546PubMedCrossRef Schmidt KL, Andersen CY, Loft A et al (2005) Follow-up of ovarian function post-chemotherapy following ovarian cryopreservation and transplantation. Hum Reprod 20:3539–3546PubMedCrossRef
21.
Zurück zum Zitat Tao T, Zhang W, Del Valle A (2009) Human oocyte cryopreservation. Curr Opin Obstet Gynecol 21:247–252PubMedCrossRef Tao T, Zhang W, Del Valle A (2009) Human oocyte cryopreservation. Curr Opin Obstet Gynecol 21:247–252PubMedCrossRef
22.
Zurück zum Zitat Woodruff TK, Snyder KA (2007) Oncofertility: fertility preservation for cancer survivors. Springer, New YorkCrossRef Woodruff TK, Snyder KA (2007) Oncofertility: fertility preservation for cancer survivors. Springer, New YorkCrossRef
Metadaten
Titel
Fertility preservation in young females with non-gynaecologic malignancy: an emerging speciality
verfasst von
C. Smyth
I. Robertson
L. Higgins
K. Memeh
M. O’Leary
M. Keane
W. Khan
K. Barry
Publikationsdatum
01.03.2014
Verlag
Springer London
Erschienen in
Irish Journal of Medical Science (1971 -) / Ausgabe 1/2014
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-013-0967-1

Weitere Artikel der Ausgabe 1/2014

Irish Journal of Medical Science (1971 -) 1/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.